What is Hepanova?
Hepanova operates at the intersection of advanced pharmacology and hepatology, specializing in the development of first-in-class therapeutics. The company's core technology platform focuses on IKKα/β inhibition, a mechanism designed to mitigate the progression of metabolic dysfunction-associated steatohepatitis (MASH) and inflammatory bowel disease. By targeting the underlying drivers of fibrosis and chronic inflammation, Hepanova is carving out a distinct market position as a developer of high-impact, oral, long-acting treatments. Their research-driven approach aims to redefine standard-of-care protocols for patients suffering from advanced liver pathology, moving beyond symptomatic management toward disease-modifying interventions.
How much funding has Hepanova raised?
Hepanova has raised a total of $83K across 1 funding round:
Debt
$83K
Debt (2021): $83K with participation from PPP
Key Investors in Hepanova
PPP
Public-Private Partnership
What's next for Hepanova?
The infusion of capital marks a pivotal transition for Hepanova as it moves deeper into clinical development. With the current funding, the firm is expected to prioritize the expansion of its clinical trial infrastructure and the optimization of its lead candidate, HPN-01. Strategic focus will likely shift toward accelerating patient enrollment and gathering robust efficacy data to support future regulatory filings. As the company matures, the emphasis will remain on validating its proprietary technology platform, potentially opening doors for strategic partnerships or further institutional backing to sustain long-term growth in the competitive biotechnology landscape.
See full Hepanova company page
